Klotho Neurosciences Provides Strategic Update Highlighting Key Milestones in Neurodegenerative Disease Pipeline

Aug 19 , 2025

NEW YORK, August 18, 2025 – Klotho Neurosciences, Inc. announced a strategic update, highlighting significant milestones that strengthen its position in the growing market for neurodegenerative disease therapies. The company is advancing its AAV-based therapeutics for conditions such as ALS, Alzheimer’s disease, and Parkinson’s disease.

Over the past year, Klotho has achieved several critical goals:

Pipeline Advancement: The company received Orphan Drug Designation from the FDA for KLTO-202 for the treatment of ALS, underscoring the therapeutic potential of its Klotho-based programs.

R&D Expansion: The company launched a new research center in Okinawa, Japan, and expanded its internal development team, boosting its capabilities in preclinical research and biomarker development.

Financial and Market Positioning: Klotho successfully raised over $11 million in financing, which eliminated its debt and helped it regain full compliance with Nasdaq listing requirements.

Independent Control: Following the mutual termination of a collaboration, Klotho now retains full global rights to its Klotho programs, giving it complete control over their development and commercialization.

Klotho CEO Dr. Joseph Sinkule stated that 2025 has been a transformative year for the company, and they are now focused on accelerating preclinical and IND-enabling studies for KLTO-202, evaluating complementary technologies, and continuing to expand internal capabilities.

Source:

https://www.prnewswire.com/news-releases/klotho-neurosciences-provides-shareholder-update-highlighting-recent-milestones-as-it-prepares-to-address-8-billion-neurodegenerative-disease-market-302531764.html

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.